A double blind crossover study was performed, in which 50 symptomatic patients with Paget disease were treated with sodium etidronate doses of 1, 2.5, 5, 10, or 20 mg/kg, or were given placebo. After 6 mth, the patients were reassigned to treatment with placebo or sodium etidronate, 5, 10, or 20 mg/kg. Sodium etidronate in dosages of 5, 10, or 20 mg/kg/day resulted in significant improvement in levels of serum alkaline phosphatase and urinary hydroxyproline, as well as clinical symptoms and bone scans. Bone scans and urinary determinations showed statistically greater improvement with sodium etidronate 20 mg/kg in comparison with patients who received sodium etidronate 5 mg/kg for 12 mth. After withdrawal of effective therapy, 5 of 9 patients continued to have remission of their symptoms with placebo for an additional 6 mth.
|Original language||English (US)|
|Number of pages||6|
|Journal||JAMA: The Journal of the American Medical Association|
|State||Published - Oct 28 1974|
ASJC Scopus subject areas